Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE

World Health Organization [portal en internet] Prevalence of diabetes worldwide; © WHO 2011 [citado 28/9/2009]. Disponible en: http://www.who.int/diabetes/facts/world_figures/en/index.html Ministerio de Sanidad: Estrategia en Diabetes del SNS [citado 15/7/2010]. Disponible en: http://www.sediabetes.org/gestor/upload/estrategia_diabetes_sistema_nacional_salud.pdf Valdés, 2007, Evolución de la prevalencia de la diabetes tipo 2 en población adulta española, Med Clin, 129, 352, 10.1157/13109554 Fu, 2009, Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions, Diabetes Care, 32, 2187, 10.2337/dc09-1128 Oliva, 2004, Direct health care costs of diabetic patients in Spain, Diabetes Care, 27, 2616, 10.2337/diacare.27.11.2616 Hart, 1997, El coste de la diabetes mellitus conocida en España, Med Clin, 109, 289 Ballesta, 2006, Economic cost associated with type II diabetes in Spanish patients, Eur J Health Econ, 7, 270, 10.1007/s10198-006-0367-9 González, 2006, Coste de la diabetes mellitus en España, Med Clin (Barc), 127, 776, 10.1157/13095815 Bottomley, 2007, Pharmaco-economic issues for diabetes therapy, Best Pract Res Clin Endocrinol Metab, 21, 657, 10.1016/j.beem.2007.08.002 Hoerger, 2009, Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes, Med Care, 47, S21, 10.1097/MLR.0b013e3181a2bf32 Jendle, 2009, Resource utilisation and costs for the treatment of diabetes in the developed world: an economical burden that needs to be solved, Int J Clin Pract, 63, 980, 10.1111/j.1742-1241.2009.02087.x Liebl, 2008, Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study, Curr Med Res Opin, 24, 2349, 10.1185/03007990802292728 Jones, 2009, Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study, Curr Med Res Opin, 25, 691, 10.1185/03007990902739669 Costi, 2010, Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation. INSTIGATE observational study in Spain, Acta Diabetol, 47, S169, 10.1007/s00592-009-0158-8 Oblikue Consulting eSALUD - Información económica del sector sanitario [citado 15/7/2010]. Disponible en: http://www.oblikue.com/bddcostes Consejo General de Colegios oficiales de Farmacéuticos: BOT base de datos de precios de fármacos [citado en 2008]. Disponible en: http://www.botplusweb.portalfarma.com/ Wild, 2004, Global prevalence of diabetes, estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Mata, 2002, El coste de la diabetes tipo 2 en Espana. El estudio CODE-2, Gac Sanit, 16, 511, 10.1016/S0213-9111(02)71973-0 The International Diabetes Federation [portal en internet]. Global Guidelines for type 2 diabetes, chapter 6: Glucose control levels; © 2005 [citado 15/7/2010]. Disponible en: http://www.idf.org/node/1285?node=1457 Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025 Gaede, 2008, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, 358, 580, 10.1056/NEJMoa0706245 Adler, 2000, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study, BMJ, 321, 412, 10.1136/bmj.321.7258.412 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 Rosenblum, 2003, Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus, J Manag Care Pharm, 9, 309, 10.18553/jmcp.2003.9.4.309 Kim, 2007, Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States, Diabetes Care, 30, 1281, 10.2337/dc06-2070 Fabunmi, 2009, Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine, Curr Med Res Opin, 25, 777, 10.1185/03007990802715199 Fuhr, 2005, Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis, Dis Manag, 8, 265, 10.1089/dis.2005.8.265 Athyros, 2009, Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study, Curr Med Res Opin, 25, 1931, 10.1185/03007990903073035 Minshall, 2005, Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States, Clin Ther, 27, 940, 10.1016/j.clinthera.2005.06.006